| abstract |
An anti-FGF23 antibody for use in a method of treating X-linked hypophosphatemia (XLH), the method comprising administering to a human subject in need of such treatment an effective amount of the anti-FGF23 antibody, wherein the antibody anti-FGF23 is administered subcutaneously every two weeks, and wherein said anti-FGF23 antibody comprises the CDR sequences of SEQ ID NO: 1, SEQ ID NO: 2, SEQ ID NO: 3, SEQ ID NO: 4, SEQ ID NO: 5 and SEQ ID NO: 6. |